Tumor therapeutics in the era of “RECIST”: past, current insights, and future prospects
Zhilong Xu, Gening Jiang, Jie Dai
Journal
- ISSN / E-ISSN
- — / —
- DOI
- 10.3389/or.2024.1435922 ↗
- Volume · Issue · Pages
- 18 · — · 1435922-1435922
- Publisher
- PagePress Publications
- Article URL
- https://doi.org/10.3389/or.2024.1435922 ↗
- Article details
- Unverified
Publication date (each date has its type and source)
18 Oct 2024
OpenAlex publication date · source: OpenAlex
| Type | Date | Source |
|---|---|---|
| OpenAlex publication date | 18 Oct 2024 | OpenAlex |
Keywords (as given): RECIST; tumor response assessment; response evaluation criteria; pseudoprogression; immune checkpoint inhibitors; neoadjuvant therapy; advanced imaging; treatment efficacy assessment
HEC Status at Publication Not the journal's current status
HEC Status at PublicationNot conclusive
Historical status could not be conclusively determined.
- Some rows of the HEC list for this period are not yet matched to a journal, so absence cannot be proved. Pending verification.
Best available information, not a definitive status: Some rows of the HEC list for this period are not yet matched to a journal, so absence cannot be proved. Pending verification.
- Journal
- Oncology Reviews
- Publication date used
- 18 Oct 2024 (OpenAlex publication date)
- Applicable HEC period
- 2024–25 (version 1) · 01 Oct 2024 – 31 Mar 2026
- Category
- —
- Recognition status
- Pending Verification (PERIOD_HAS_UNMATCHED_ROWS)
- Source
- —
- Verification status
- Unverified
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.
